Literature DB >> 29112487

Pharmacotherapy for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: A Systematic Review.

Claire M Lawlor1, Ashwin Ananth1, Blair M Barton1, Thomas C Flowers1, Edward D McCoul1,2,3.   

Abstract

Objective Angioedema is a potentially life-threatening complication of angiotensin-converting enzyme inhibitor (ACEI) use, occurring in up to 0.5% of users. Although the pathophysiology of ACEI-induced angioedema is attributable to elevated serum bradykinin, standard management typically includes corticosteroids and antihistamines. We sought to summarize the evidence supporting pharmacotherapy for ACEI-induced angioedema. Data Sources PubMed, MEDLINE, and Embase portals. Methods A systematic literature review was conducted according to the PRISMA guidelines. Databases were queried by 3 independent reviewers for English-language studies published between 1980 and 2017. The initial search screened for all occurrences of "angioedema" and then was further refined to include studies of ACEI-related cases and exclude hereditary angioedema. Results Five articles representing 218 cases were identified, including 3 randomized controlled trials and 2 prospective case series with historical controls. One of 2 studies of icatibant (bradykinin B2 receptor antagonist) found more rapid symptom improvement than that with a control group of corticosteroids and antihistamines. Two studies of ecallantide (plasma kallikrein inhibitor) and 1 study of C1 inhibitor replacement found no significant benefit over control. No studies were identified that compared the efficacy of corticosteroids with antihistamines, of one dose with another, of fresh frozen plasma, or of combination therapy. Conclusion The efficacy of treatment of ACEI-induced angioedema with bradykinin antagonists, kallikrein inhibitor, and C1 inhibitor warrants further study. Although consistent benefit of these medications has not been demonstrated, their use has not caused harm. One study examining off-label use of icatibant has demonstrated efficacy over control. In addition, further study is needed to establish the efficacy and mechanism of action of standard pharmacotherapy such as corticosteroids and antihistamines in treatment of this condition.

Entities:  

Keywords:  ACE inhibitor; angioedema; angioneurotic edema; pharmacotherapy

Mesh:

Substances:

Year:  2017        PMID: 29112487     DOI: 10.1177/0194599817737974

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

Review 1.  [The ulm emergency algorithm for the acute treatment of drug-induced, bradykinin-mediated angioedema].

Authors:  J Hahn; B Bock; C-M Muth; A Pfaue; D Friedrich; T K Hoffmann; J Greve
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-09-19       Impact factor: 0.840

Review 2.  [Allergic emergencies].

Authors:  A-C Herr; T Biedermann; K Brockow
Journal:  Hautarzt       Date:  2018-05       Impact factor: 0.751

3.  A Case Report of Lifesaving Intravenous Bolus Epinephrine Administration in a Case of Severe Refractory Anaphylactic Shock.

Authors:  Mustafa Hammad; Noora Adam; Khurram Sarfaraz; Maryam Adam; Naser Mansoor
Journal:  Cureus       Date:  2022-08-22

4.  Fatal outcome of late-onset angiotensin-converting enzyme inhibitor induced angioedema: A case report.

Authors:  Jone Jackeviciute; Vidas Pilvinis; Rugile Pilviniene
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

5.  Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment.

Authors:  Eva Rye Rasmussen; Pär Hallberg; Ekaterina V Baranova; Niclas Eriksson; Malgorzata Karawajczyk; Caroline Johansson; Marco Cavalli; Cyrielle Maroteau; Abirami Veluchamy; Gunilla Islander; Svante Hugosson; Ingrid Terreehorst; Folkert W Asselbergs; Pia Norling; Hans-Erik Johansson; Hugo Kohnke; Ann-Christine Syvänen; Moneeza K Siddiqui; Chim C Lang; Patrik K E Magnusson; Qun-Ying Yue; Claes Wadelius; Christian von Buchwald; Anette Bygum; Ana Alfirevic; Anke H Maitland-van der Zee; Colin N A Palmer; Mia Wadelius
Journal:  Pharmacogenomics J       Date:  2020-02-21       Impact factor: 3.550

6.  Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy.

Authors:  William Lumry; Teri Templeton; Laurel Omert; Donald Levy
Journal:  J Infus Nurs       Date:  2020 May/Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.